Using allogeneic stem cells to fight Parkinson's, clinical trials are successfully advanced

March 27, 2022 / eMedClub News / -- On March 24, 2022, IMAC Holdings announced that its allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of Parkinson's disease-induced bradykinesia have initiated Phase 1 The third and final cohort of the clinical trial
.

Parkinson's disease (PD) is the second most common chronic progressive neurodegenerative disease after Alzheimer's disease, affecting nearly 10 million people worldwide
.

It is estimated that the prevalence of PD among people over 65 years old in China is 1700/100,000, and the prevalence rate of people over 70 years old is 3% to 5%, with nearly 100,000 new cases every year
.

As the world ages, the number of people suffering from the disease is likely to increase further
.

 Parkinson's disease is the misfolding and abnormal accumulation of α-synuclein in the central and peripheral nervous systems, leading to progressive deterioration of motor and non-motor symptoms throughout the body.
It is a chronic neurodegenerative disease that endangers the health of middle-aged and elderly people.
, The main clinical manifestations include tremor of hands and feet, body stiffness, slowness of movement and so on
.

 In addition to abnormally slow movements and reflexes, the bradykinesia caused by Parkinson's disease can lead to limited ability to lift arms and legs, reduced facial expression, muscle stiffness, staggering walking, and difficulty with repetitive movements, self-care, and daily activities
.

Parkinson's disease is the classic culprit of bradykinesia, a patient's ability to move and react less as the disease progresses
.

 This Phase 1 clinical trial of IMAC included a dose-escalation safety and tolerability study of 15 patients divided into three groups: 1) 5 patients with Parkinson's disease-related bradykinesia who received a low-dose intravenous infusion of stem cells , to be completed on February 26, 2021; 2) five patients will receive a mid-dose intravenous infusion, to be completed on February 16, 2022, 3) and five patients will receive a high-concentration dose intravenous infusion
.

Dr.
Ricardo Knight, medical director of the Mike Ditka IMAC Center for Regeneration, is the lead investigator of the trial
.

 Stem cell therapy for Parkinson's disease The main mechanism of stem cell transplantation in the treatment of Parkinson's disease is to induce and differentiate into dopaminergic neurons to play a role in cell replacement; it can also be used to secrete neurotrophic factors, immune regulation, etc.
to play neuroprotective functions and promote damaged dopamine.
neuron repair
.

In recent years, stem cell therapy for Parkinson's disease has attracted much attention, and related clinical trials have also been carried out
.

 In November 2018, Kyoto University in Japan announced that its researchers had carried out the first clinical trial of using induced pluripotent stem cells (iPS cells) to treat Parkinson's disease, transplanting nerve cells cultured from iPS cells into a patient's brain.
progenitor cells
.

The surgery was completed in October on a man in his 50s who was transplanted with dopamine neural progenitor cells derived from allogeneic iPSCs
.

During the roughly three-hour transplant, doctors injected about 2.
4 million dopamine neural progenitor cells into the patient's brain
.

Recommended reading: Japan's first use of iPS cells to treat human Parkinson's diseaseYimai Meng broke the news The first dose of DA01 has been completed and it has entered the phase 1 clinical safety and tolerability study
.

In July of the same year, the drug received fast-track certification from the US FDA
.

Recommended reading: Bayer’s strong deployment of innovative Parkinson’s therapies, stem cells and gene therapy have entered the clinical stage Yimai Meng broke the news FDA approves a Phase 2 clinical trial (NCT04928287) of allogeneic adipose-derived mesenchymal stem cells, multiple intravenous infusions, for the treatment of Parkinson's disease The role of activities of daily living and quality of life in patients with Kinson's disease
.

Recommended reading: Autologous and Allogeneic at the same time! Parkinson's Stem Cell Therapy Enters Phase 2 Clinical Yimai Meng broke the news Stem cells have become an important research trend in the treatment of Parkinson's disease
.

With the progress of research and the further deepening of the understanding of the main causes of the disease, stem cell therapy is expected to show breakthrough achievements in the field of Parkinson's disease treatment, reduce the disease burden for the majority of patients, and bring about significant improvements in the quality of life
.

 Reference: https://ir.
imacregeneration.
com/news-releases/news-release-details/imac-holdings-inc-announces-initiation-third-and-final-cohort--a list of recent popular events-▼3 On March 29, key points of nucleic acid drug industry development analysis and process development ▼ On March 31, authoritative interpretation of AAV gene therapy drug characterization analysis technology ▼ On March 31, Guangzhou, the theme salon of quality control challenge of virus delivery vector AAV ▼ July 1st-3rd, Shanghai, 2022 Shanghai International Bio-Innovative Drug Industry Expo